OK so you thought the title of the other thread was out of date BUT unfortunately there is no way to edit thread titles.

So here is a new title

This one has got the charts at the top again & has a link to the old one.
http://www.moneyam.com/InvestorsRoom/posts.php?tid=5021

OXFORD BIOMEDICA PLC

RESULTS OF FIRM PLACING AND PLACING AND OPEN OFFER

On 13 December 2010, the Board of Oxford BioMedica plc (the "Company" or "Oxford BioMedica") announced details of a proposed share issue to raise gross proceeds of GBP20 million (GBP18.4 million net of expenses) by way of a firm placing of 278,916,543 new ordinary shares of 1 pence each (the "New Ordinary Shares") (the "Firm Placing") and a placing and open offer of up to 121,083,457 New Ordinary Shares (the "Placing and Open Offer)" at a price of 5 pence per New Ordinary Share.

Defined terms used in this announcement shall have the same meaning as those terms defined and used in the prospectus of the Company dated 13 December 2010.

The Open Offer closed for acceptances at 11.00 a.m. on 6 January 2011. At that time the Company had received valid acceptances in respect of 115,756,980 Open Offer Shares from Qualifying Shareholders. This represents approximately 95.6 per cent. of the Open Offer Shares offered. All eligible applications received from Qualifying Shareholders will be allocated their pre-emption entitlements and all eligible applications under the Excess Application Facility will be allocated their Open Offer Shares as applied for.

The Firm Placing and Placing and Open Offer remain conditional, amongst other things, upon the passing of the Resolutions at the General Meeting to be held at 10.00 a.m. on 7 January 2011 and Admission occurring no later than 8.00 a.m. on 10 January 2011 or such later time or date as the parties to the Placing Agreement may determine.

Application has been made to the UK Listing Authority for the New Ordinary Shares to be admitted to the premium segment of the Official List and to the London Stock Exchange for the New Ordinary Shares to be admitted to trading on the London Stock Exchange's main market for listed securities. It is expected that Admission will become effective on 10 January 2011 and that dealings in the New Ordinary Shares will commence at 8.00 a.m. on 10 January 2011. Thereafter, Oxford BioMedica will have a total of 944,875,557 Ordinary Shares in issue.

The New Ordinary Shares, when issued and fully paid will rank equally in all respects with the Existing Ordinary Shares.

This announcement should be read in conjunction with the full text of the Prospectus. A copy of the Prospectus is available at the UKLA's National Storage Mechanism and will be available for inspection at www.hemscott.com. In addition, the Prospectus is available to view on the Company's website (www.oxfordbiomedica.co.uk). Copies of the Prospectus are also available from the offices of Oxford BioMedica plc, Medawar Centre, Robert Robinson Avenue, The Oxford Science Park, Oxford, OX4 4GA.

A good report back from a ADV.. poster.. that was at the meeting today..


7 Jan'11 - 16:58 - 8755 of 8763

"I arrived 45 minutes early quite deliberately and was, as I suspected, immediately recognised by Alan Kingsman. Having previously exchanged emails he knew what my concerns were and so we spent just over 20 minutes before the meeting going over them. This was followed by John Dawson approaching me (as a result of my tete a tete with Prof Kingsman) and a further 10 to 15 mins one to one ensued.

As a result, I made no comments DURING the meeting and stuck my hand up to approve each proposal (which was going to pass anyway).

What did I learn?

1. Whether WE like it or not JD and the whole board are convinced that current and ongoing negotiations are influenced strongly by the lack of a cash pipeline. They have been planning the cash raising for many months and believe that the market have been selling down the SP from 12p to 10p to 8p SOLELY because of the cash runway. They were afraid that to wait longer would mean a drop to 6p and a cash raising would then have to be at 4p or thereabouts.
JD claims his experience tells him that serious big players track their target for a period of 2 years quite typically and will rather pay a multiple of a figure discussed at earlier stages for the satisfaction of de-risking.

2. JD claims this fund raising hurt him too as he chose shares over a cash payment when he joined and has had to pay out for his share of the fund raiser. (I said Sure, but youll vote yourself enough share options in due course and a modest debate ensued between us)

3. To the question wont there be another cash call in 2012 he said we will not do another cash call.



Note: interesting statements from the Prof, JD and Andrew Wood DURING the meeting with regard to the issue of the underwriting fees, leaks, etc.
They clearly dont have much regard for the City. They called around a lot of institutions with regard to the fund raiser and they all quoted similar (high) charges. The Prof in particular hates the leaking but has become inured to it. He says whenever you decide to GO with a fund raising, institutions are offered participation (and they become insiders), It shouldnt, but it always leaks, and there is nothing you can do about it. It is part of the justification the City use for the heavy discount (that the SP will sink prior to the actual announcement). You cant do anything because the only recourse is to pull the fund raiser and the effect of that on the SP is even worse.

4. Factory. The capital cost of the factory is only 1.9m (it IS the one in Oxford as predicted by Martin C-J). Therefore the cash runway is extended much further than some of us feared as they have put in the running costs (including staff) in the figures used for the disposition of the funds. Why this matters is as follows:-
When they do a P2 trial it can cost them 1m for a manufacturer to make the product, they will save the bulk of that sum with each of the P2 trial on the ocular product in 2011/2012.
There are very few contractors in the world that can make, for example, Lentivector product. This creates real problems in scheduling and therefore timing.
They believe that Sanofi will PREFER OXB to be the manufacturer for the ocular products not only through trial but also through marketing.

5. PROSAVIN They showed us the (talked about) video of the star patient from the very first cohort at the 1X dose. The first video was done before dosing (in l-dopa OFF) and the second done 2 years after dosing so no question of placebo effect. Each video shows a man seated at the left hand end of a wall, he gets up, walks along the wall to the end, turns around, then walks back to the chair. In the before we see a delayed lift off from the chair in a very unsteady movement, a slow and shuffling unsteady gait, a halt at the end (wanting to turn around but body not obeying), then almost falling as the slow turn is made, followed by the stooped shuffle back.
In the after his rise from the chair looks completely normal, his gait remains a little stooped but clearly confident and at normal speed, the turn around at the end of the wall would have been worthy of 4 10s on Come Dancing (or whatever it is now called!).
There can be NO QUESTION THAT PROSAVIN WORKS even at low doses, but now for the complexities of the situation:-
- Prof Kingsman explains that dosing using biological products is inherently inaccurate;
- The spread (not the terms the Prof used) or take up of Prosavin and similar into the brain cells is also variable;
- Monkeys sit in a cage, are given fixed amounts of food, do same things every day, are zapped to a nil dopamine state are predictable. Human patients are NOT consistent (except in the fact that they are all failing on l-dopa but some worse than others), they turn up for their treatment, then turn up for their review meetings on FIXED dates. If the patient is ill that day, they still have to use that days measurements. Patients have (anecdotally) had a close relative die within a couple of days of the process; or in another case felt so good they thought they would spend a week or two completely redecorating their house, turning up for their measurement completely knackered! - point is human patients NOT CONSISTENT.
- 1x and 2x doses were similar, therefore not much expected of 2x (also confirms that 1x and so on are just labels not strict ratios.
- Stuart Naylor confirms that the 2x INFUSION candidates were much more severely Parkinsonian than earlier candidate.

(I had a bit of a debate with he and the Prof about putting a little more laymans script around their RNS. Explain a little more about the conditions, what they expected to get, etc. Their professional attitude to this is that they wont do it as it could lead to wrong interpretation, I argued the opposite. I didnt win!

- We need to remind ourselves that the trials so far are only about toleration and dose escalation
- It seemed fairly clear to me that they dont consider themselves expert in the dose administration and my impression was that the infusion method was brought to them by the experts on the administration as it has previously been used by another drug development company.
- They clearly EXPECT the 5x dosing to give all candidates a consistent level of improvement i.e. remove all Parkinsonian symptoms. Results will be available in JUNE 2011 and JD expects to do the sort of deal that is acceptable pretty quickly following that. (It may be counterintuitive to the like of us, but JD claims that big pharma (even if the believe the science) will only do a deal when it is de-risked.
- The deals (and there have apparently been a number) offered have all been much too low for what JD believes is a billion $ drug.
- Cambridge centre is set up now so following the first two individual candidates for 5x infusion being done consecutively they and Paris will process candidates in parallel. Cambridge, Addenbrookes, Roger Barker.

The threshold dose point that I posted earlier is not really right. More accurately, there is a dose level in monkeys (5x equivalent) where ALL candidates improve consistently to a mean.
In the primates, when they then de-escalated the doses, they got exactly the same results as they are getting with low dose humans very variable.

5. TROVAX Trovax works and will pass a suitable P3 in due course (although as Stuart Naylor explained they will need to partner it and at present the stigma of a failed P3 still surrounds the product. There IS a lot of interest and, like Prosavin deal candidates, these are people who want to stick around for a year or two to see the product de-risked before they will negotiate seriously.
They have to earn back respect with the blinded P2s with placebo arm that are already planned. Interesting there IS a study, which has gone for peer review that starts with the findings about blood status that came out of Trist and reviews ALL the previous P2s they did. The study shows that the good blood findings from Trist are consistent in all the P2s. This SHOULD make a good story to tell.
BTW the East European centre had mostly candidates with very poor blood condition (Stuart explains that as a cancer sufferer approaches the end game not his words a common condition is a thickening of platelets and other problems).


SUMMARY: (All IMHO) They won me over but the timescale is a minimum 6 months before big news (5x infusion 3 month results), more likely a year (Big Prosavin deal), really good in 2 years (ocular products into clinic and Trovax P3 deal)"

t
re your post 1346.
now why would i want to construct such a thread?
i just question all posters who proclaim themselves to be invincible, as in,"never wrong".
if they respond and wish to have a nice intellectual conversation about it then that is fine with me.it is unfortunate however if that response is abusive.
fortunately it rarely is, abusive that is, apart from your replies which mostly are, but not always, just mostly. maybe it is t who dislikes jkd.
have a nice weekend.
regards
jkd

JkdI dont dislike youI dont know you?I call myself thick and lucky.and have posted that on a regular basisI have also posted the hit I took on mdxwhich doesnt make me invinciblealthough very close?.now let me see you have called me a liarabusivearrogantand at one point accused me of coming on to a married lady on these threadsin a polite manner of course!I wouldnt mindonly the lady in question scares the life out of meplus I am a very happily married man with a nice familyanywaylet others decide?
No need for a responseunless you have some intellectual conversation about OXB

ok thats fair enough about this OXB thread
i'm off.
agree with you.let others decide
regards
jkd
edit & ps you are the red herring man. what was the original point of these posts?
seems a red herring has intervened or rather been introduced by you on the last post just to mudddy the waters maybe.

t
additionally, would you like me to now tear all your posts to pieces? including the last one bit by bit?
as you tried and failed to do so about my previous posts?
thank you for your request for me to not require to respond. i do understand.for your own sake please do stop digging. i will throw you a rope at some stage.what you use it for is up to you.
regards to you
jkd

Jkdso I am a red herring now?.love you you aint half a pilchard grandad

Anywayhasnt the 20mil got to add a penny or so to the SP?the price took a hit with the dilutionbut the cash is in the bank!any views?

Yes my allocation has not yet arrived but paid for 30 Dec. Thought they would arrive 10 Jan - any views or news

havent got my allocation yet either

My broker tells me that they will arrive into my acct to-day. They are looking into reason for delay.

allocation has arrived now

Good to read the Kingsman family has bought 2m shares, admitidly this buy is at a massive discount to the selling price (39p was it?) a few years ago. At that time it looked sttrange, just before an AGM, but the Co PR machine was well polished and no-one worried...too much.

Nice to think sp might reach those old levels - - -
About time; I've been in since 1999....Grief!

Me too and my enlarged prostate !!

my post 1352 edited with a small addition of 4 words today.
regards
jkd

Jkdground breaking news!

http://www.oxfordbiomedica.co.uk/userfiles/file/pdfs/OBM0111JPM.pdf

Market chatter suggests gene-therapy company Oxford BioMedica (OXB)
is very close to closing a deal to purchase a UK manufacturing facility so it can establish in-house drug production. Buy ahead of the deal being confirmed. Oxford wants its own capacity as it has five other products in clinical development, including a cancer vaccine, Trovax, in Phase II trials. (CM)
Shares says: Speculative Buy at 5.5p

I read that rumour too, (was it you?), but I'm not convinced, unless there is a facility on the cheap.... for they need the Rights money and would have have to have told subscribers/shareholders what they were doing...as that was a while ago (yep!) I think this cash is for working capital...that was what we were told...(anyone?).

Still, often wrong, it would make sense to buy a small Bio-dev.Co. that needed their contacts. Whereas I don't think OXB needs a manufacturing facility - I understood they had some Trovax made a while back and this is still in the fridge. Trials-volume req'd isn't enough to start a production. However, if they can secure a bread-n-butter product, that changes everything.
+ I bought a few more at these lows....but I'm wary we've been seeing lows . . . . . . for rather too long.

HangonI wrote to the company some time ago concerning the manufacturing facilityalong with some other questions

This is part of the reply I received from Lara


"Dear *******


Regarding the manufacturing point you have raised below, we have an exclusive option to acquire a UK-based manufacturing facility at a fraction of the cost of a new-build. We currently have one Phase I/II product, ProSavin, which utilises our EIAV-based LentiVector technology platform (EIAV stands for our equine infectious anemia virus which we use to deliver the genes), however we have four LentiVector-based ocular products, partnered with sanofi-aventis, moving into clinical development over the next 18 months. This moves us from one LentiVector-based programme to five clinically active programmes.

We estimate that it will take about 12 months to bring the manufacturing unit on-stream, but thereafter, based on present plans, the amount of clinical-grade material that our development programmes will require could make the manufacturing unit cost-effective. With five LentiVector products moving from Ph I/II through to Ph II, Ph III and the market, we plan to support our five programmes with control of supply and we would eventually also have the opportunity to be the preferred supplier for our commercial partners.

I hope this provides some clarity.

Best wishes,
Lara"

I now believe OXB are developing the business on privileged information and assurances from partnersthe 18.4ml netwill fund ProSavininvest in manufacturing infrastructure for the LentiVector programmesstrengthen the balance sheetwhich will give OXB a stronger negotiating position for partnering dealsand take us way past the first catalysts associated with the ocular assetsthere is also double digit million dollar milestone paymentswhen Sanofi exercise one or more of the ocular programmesall in all hangonwe now look pretty damn strong

kiss of death!

We have had all the bad news pricedI will be very surprised if the SP is not considerably higher come this date!

Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE: OXB), today announces that it will be releasing its preliminary results for the twelve months ended 31 December 2010 on Wednesday 2 March 2011.
An analyst briefing will be held at 9:30am GMT on Wednesday 2 March 2011 at the offices of M:Communications, CityPoint, 1 Ropemaker Street, London, EC2Y 9AW.
Simultaneously to the analyst briefing at 9:30am GMT, there will be a live audio webcast of the presentation. To connect to the webcast facility, please visit the Company's website: www.oxfordbiomedica.co.uk approximately 10 minutes (9:20am GMT) before the start of the briefing. A replay will be made available shortly after the presentation.